Illumina News and Research

RSS

Federal Circuit affirms dismissal of Illumina's patent infringement lawsuits against Affymetrix

Affymetrix, Inc. today announced that the U. S. Court of Appeals for the Federal Circuit has affirmed the dismissal of the patent infringement lawsuits brought against the Company by Illumina regarding U.S. Patent Nos. 7,510,841 and 7,612,020.

From Illumina, Inc. 22 Aug 2011

Illumina and University of Oxford collaborate to sequence whole genomes

Illumina, Inc. today announced it will collaborate with the University of Oxford to sequence the whole genomes of 500 individuals afflicted with a range of life-threatening diseases that pose major challenges in diagnosis, treatment, and care. Illumina HiSeq™ 2000 systems will be used to generate sequence data for the 500 genomes.

From Illumina, Inc. 3 Aug 2011

Illumina board authorizes new $100 million share repurchase program

Illumina today announced that on August 1, 2011, its Board of Directors authorized the Company to repurchase, on a discretionary basis, up to $100 million of its outstanding common shares in the open market or in privately negotiated transactions, subject to market conditions and other factors. The previous discretionary $100 million share repurchase program authorized in July 2010 was completed this week.

From Illumina, Inc. 3 Aug 2011

Illumina begins to ship HumanOmni5-Quad DNA Analysis BeadChip

Illumina, Inc. today announced that it has begun shipping the HumanOmni5-Quad DNA Analysis BeadChip (Omni5), the new flagship array of the Omni family of microarrays.

From Illumina, Inc. 25 Jul 2011

Illumina announces availability of new TruSeq Custom Enrichment kits

Illumina, Inc. today announced availability of its new TruSeq Custom Enrichment kits which enable researchers to economically design and target genomic regions of interest ranging from 700 kilobases (Kb) to 15 megabases (Mb) of cumulative DNA.

From Illumina, Inc. 13 Jul 2011

Illumina, Sequenom sign three-year supply agreement

Sequenom, Inc., a life sciences company providing innovative genetic analysis solutions, today announced it has signed a three-year supply agreement with Illumina, Inc., a leading developer and manufacturer of life sciences tools for the large-scale analysis of genetic variation and function.

From Illumina, Inc. 11 Jul 2011

Nature journal publishes landmark genetic study of ovarian cancer

A University of Houston researcher is an author on a landmark multi-institutional genetic study of the most aggressive and common form of ovarian cancer that is published in the current issue of the scientific journal Nature.

11 Jul 2011

Gene Codes releases Sequencher 5.0

Gene Codes Corporation announces the release of Sequencher 5.0. It incorporates new DNA sequence data alignment algorithms with SNP and methylation analysis for next-generation DNA sequence data. Performance for assembly and alignment of sequences and contigs is hundreds of times faster.

28 Jun 2011

BGI releases third version of assembled E. coli O104 genome

Scientists worldwide have been working on the publicly available genomic sequences of the deadly E. coli O104 strain, which is causing the current health crisis in Germany and now spreading throughout Europe. To continue to speed the ongoing international efforts of researchers to assess and halt this growing epidemic, BGI and their collaborators at the University Medical Centre Hamburg-Eppendorf have now released their third version of the assembled genome, which includes new data from this E. coli O104.

8 Jun 2011

GenoLogics enhances LIMS software for next-generation genomics labs

GenoLogics, a leading provider of laboratory information management system (LIMS) software for next-generation genomics labs, today announced a detailed product roadmap for its eponymous LIMS, designed to provide the scalability, adaptability and usability features necessary for mainstream adoption of the most advanced sequencing technologies while supporting existing genotyping platforms.

11 May 2011

Illumina announces price reduction in whole human genome sequencing projects

Illumina, Inc. today announced that it is significantly reducing the price for sequencing whole human genomes through the Illumina Genome Network.

From Illumina, Inc. 9 May 2011

Oxford Nanopore raises $41 million via private placement of ordinary shares

Oxford Nanopore Technologies Ltd., the UK-based developers of nanopore technology for the direct, electronic analysis of single molecules, today announced that it has raised £25 million in new funding via a private placement of ordinary shares in the Company.

From Oxford Nanopore Technologies 26 Apr 2011

Trial of non-invasive prenatal test to determine Down syndrome successful

At the moment, the only reliable way of diagnosing chromosomal irregularities during pregnancy is to use invasive prenatal methods. This causes miscarriage in about one per cent of these risky surgical procedures.

14 Apr 2011

UC researchers sequence individual glioblastoma genomes and track abnormalities through the bloodstream

Medical scientists know this about glioblastoma multiforme: the malignant brain tumor is aggressive, it is elusive, and it appears in different permutations.

5 Apr 2011

Clontech launches new SMARTer Ultra Low RNA Kit

Clontech Laboratories, Inc., a wholly-owned subsidiary of Takara Bio Inc., today announced the launch of its SMARTer Ultra Low RNA Kit for Illumina Sequencing, which was developed in collaboration with Illumina, Inc.

31 Mar 2011

Illumina prices 0.25% Convertible Senior Notes due 2016

Illumina, Inc. today announced the pricing of $800 million principal amount of 0.25% Convertible Senior Notes due 2016 through offerings to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended.

From Illumina, Inc. 15 Mar 2011

Scientists sequence Clostridium botulinum genome that produces neurotoxin

Scientists on the Norwich Research Park have sequenced the genome of a novel strain of Clostridium botulinum, one of the most dangerous pathogens known to man. The strain produces an unusual botulinum neurotoxin, known as type A5 neurotoxin, which was isolated by the Health Protection Agency, following a case of wound botulism.

8 Mar 2011

Scientists discover SNPs linked with high risk of sick sinus syndrome

Scientists at deCODE genetics and academic colleagues from Iceland, The Netherlands, Denmark, USA and Illumina, Inc., today report the discovery of single-letter variants in the sequence of the human genome associated with high risk of sick sinus syndrome.

6 Mar 2011

Accelrys releases Pipeline Pilot NGS Collection at Molecular Medicine Tri-Conference

Accelrys, Inc. (NASDAQ:ACCL), the leading scientific informatics software and services company, today announced at the Molecular Medicine Tri-Conference its entrance in the rapidly growing next generation sequencing (NGS) market with the release of the NGS Collection for Pipeline Pilot.

24 Feb 2011

Macrogen announces formation of Axeq Technologies in the US, Europe and Asia

Macrogen, Inc announces the formation of Axeq Technologies, a US-based division with operations and offices in the US, Europe and Asia. "Axeq" is a premium brand representing a whole new experience and industry-leading standards in DNA sequencing service.

22 Feb 2011